Építés alatt – nem éles oldal
Belépés
Leállítva3. fázis

Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

A legfontosabb adatok

Ki végzi
Apollomics Inc.
Hol
Kína2 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Leállítva
Fázis
3. fázis
Résztvevők
140 fő vett részt
Kezdés
2021. nov. 17.
Befejezés
2024. aug. 22.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Uproleselan
  • Placebo
A regiszteradat frissítve
2025. június 27.
Miért állt le
In light of the strategic realignment of the company's development focus, it has been determined to discontinue the further development of Uproleselan Injection.

Ki vehet részt

Életkor
18 év – 75 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • ≥18 years and ≤75 years in age
  • AML diagnosed with ≥20% myeloid marrow blasts or peripheral blood blasts per WHO criteria(2008) at the time of initial diagnosis
  • For subjects with primary refractory AML:; Refractory disease is defined as persistent disease (≥5% blasts in the bone marrow) at least 28 days after initiation of anthracycline-containing induction therapy or relapse from a first remission (CR, CRi, complete remission with incomplete platelet recovery [CRp], CRh) lasting for <90 days. Isolated extramedullary disease is not allowed; Persistent disease (≥5% blasts in the bone marrow): Must have received 1 (and only 1) prior anthracycline-containing induction regimen. Except as defined below, a second induction with intent to induce remission is not allowed; Re-induction within 28 days with a comparable regimen containing the same chemotherapy agents (e.g., cytarabine/daunorubicin '7+3' and '5+2'; or cytarabine/daunorubicin '7+3' and '7+3') is allowed; Re-induction within 28 days with a comparable regimen using an alternative anthracycline (e.g., cytarabine/daunorubicin in the first induction and cytarabine/idarubicin in the second) is allowed; Previous induction with certain regimens (venetoclax/hypomethylating agent [HMA], venetoclax/LDAC, single agent HMA) followed by an anthracycline induction regimen is allowed. May have achieved remission with certain regimens (venetoclax/HMA, venetoclax/LDAC, single agent HMA) and then experience relapse now refractory to anthracycline-containing induction; Relapse from first remission (CR, CRi, CRp, CRh) lasting <90 days: 1) After achieving first remission from any induction regimen, may have received consolidation before experiencing relapse
  • No more than one prior stem cell transplant
  • Has not received the chemotherapy regimen to be used for induction on this trial
  • Is considered medically eligible to receive the chemotherapy regimen to be used for induction on this trial
  • Peripheral absolute blast count (ABC) ≤40.0 x 109/L (ABC = total white blood cells [WBC] x blast % in peripheral blood). Hydroxyurea to control absolute blast count is allowed prior to uproleselan/placebo dosing
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2

Ki nem vehet részt

  • Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing
  • Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing
  • Major surgery within 4 weeks before uproleselan/placebo dosing
  • Active signs or symptoms of CNS involvement by malignancy (No lumbar puncture required)
  • Known active infection with hepatitis A, B, or C, or human immunodeficiency virus
  • Uncontrolled acute life-threatening bacterial, viral, or fungal infection
  • Myocardial infarction within 6 months of uproleselan/placebo dosing, or subject has current significant cardiovascular disease
  • Allogeneic HSCT ≤ 4 months, autologous HSCT ≤ 3 months or donor lymphocyte infusion (DLI) ≤ 6 weeks prior to Uproleselan/placebo dosing
  • Creatinine clearance <45 mL/min (Cockcroft-Gault method) or creatinine >1.5x ULN (any assessed must be within eligibility limit)
  • Patients with acute promyelocytic leukemia
  • Acute leukemia of ambiguous lineage (biphenotypic leukemia)
  • Chronic myeloid leukemia with myeloid blast crisis
  • Inadequate organ function
  • Abnormal liver function

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This bridging study will evaluate the efficacy of uproleselan, a specific E-selectin antagonist, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML

A vizsgálat 2 csoportja

  • UproleselanA vizsgált kezelés

    Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Uproleselan in combination with HiDAC/IDAC during consolidation

  • Placebo (Saline, 0.9% Sodium Chloride)Placebo, összehasonlításként

    Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Placebo in combination with HiDAC/IDAC during consolidation

    Kezelés: Placebo

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 3 Randomized, Double-Blinded Bridging Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Chinese Patients With Relapsed/Refractory Acute Myeloid Leukemia
A regiszteradat frissítve
2025. június 27.